Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 223.71M P/E - EPS this Y - Ern Qtrly Grth -
Income -61.98M Forward P/E -3.70 EPS next Y - 50D Avg Chg -6.00%
Sales 7.04M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 0.89 EPS next 5Y - 52W High Chg -17.00%
Recommedations 2.70 Quick Ratio 13.09 Shares Outstanding 32.87M 52W Low Chg 10.00%
Insider Own - ROA -16.58% Shares Float 16.99M Beta 0.78
Inst Own 2.63% ROE -30.12% Shares Shorted/Prior 56.36K/49.02K Price 6.08
Gross Margin - Profit Margin - Avg. Volume 1,038 Target Price 9.03
Oper. Margin -1,613.18% Earnings Date - Volume 619 Change -0.41%
About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG News
04/19/24 Life Science Cares Launches in Switzerland
04/17/24 Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
08:26 AM Molecular Partners Publishes Invitation to Annual General Meeting 2024
03/14/24 Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
03/13/24 The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable
03/01/24 Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
01/07/24 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
01/05/24 Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
12/22/23 Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%
12/14/23 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
12/10/23 Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
11/14/23 Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
11/09/23 We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
11/03/23 Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
11/02/23 Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
11/01/23 Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
03:00 PM Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
10/05/23 Shareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years ago
09/13/23 Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
08/24/23 Molecular Partners Reports H1 2023 Corporate Highlights and Financials
MOLN Chatroom

User Image Stock_Titan Posted - 1 week ago

$MOLN Life Science Cares Launches in Switzerland https://www.stocktitan.net/news/MOLN/life-science-cares-launches-in-e224npomazzp.html

User Image Stock_Titan Posted - 1 week ago

$MOLN Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting https://www.stocktitan.net/news/MOLN/molecular-partners-announces-all-board-proposals-approved-at-the-m8eqq3uee58j.html

User Image HaltTradeAlert Posted - 2 weeks ago

$MOLN Halt Time: 15:19:46 Issue Symbol: MOLN Reason Code: LUDP Stock Price: $3.9700 Market Cap: 130.49M Volume: 9,678 Relative Volume: 3.14 Shares Float: 16.99M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image HaltTradeAlert Posted - 2 weeks ago

$MOLN Halt Time: 14:41:07 Issue Symbol: MOLN Reason Code: LUDP Stock Price: $3.9300 Market Cap: 129.175M Volume: 9,003 Relative Volume: 2.92 Shares Float: 16.99M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image HaltTradeAlert Posted - 3 weeks ago

$MOLN Halt Time: 09:40:43 Issue Symbol: MOLN Reason Code: LUDP Stock Price: $3.9000 Market Cap: 128.132M Volume: 1,066 Relative Volume: 0.08 Shares Float: 16.99M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image Stock_Titan Posted - 1 month ago

$MOLN Molecular Partners Publishes Invitation to Annual General Meeting 2024 https://www.stocktitan.net/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-1pmvo2582qbe.html

User Image Stock_Titan Posted - 1 month ago

$MOLN Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 https://www.stocktitan.net/news/MOLN/molecular-partners-reports-corporate-highlights-from-q4-2023-and-key-kyhl71xylyia.html

User Image Chris_84 Posted - 1 month ago

$MOLN Hot off the presses! Read Molecular Partners’ SVP of Oncology Research, Daniel Steiner’s blog post on #RadioDARPin Therapy discovery at MP; what we’ve achieved and why it matters for this rapidly growing space in cancer treatment. https://lnkd.in/eQbWkbCY

User Image TickerDD_com Posted - 1 month ago

From 3/1/2024, looking back across 22 Month-Ends for MOLN, Percentage Change of Average Monthly Price had More Negatives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $MOLN #MOLN #MOLNStock #TickerDD #MOLNPrice https://www.youtube.com/watch?v=b6L2UdsYtsw

User Image Ninja_Tradez Posted - 1 month ago

📢 $MOLN - Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations https://newsfilter.io/a/108d3537a2146931013b57c750b16d06

User Image Stock_Titan Posted - 1 month ago

$MOLN Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations https://www.stocktitan.net/news/MOLN/molecular-partners-to-hold-conference-call-to-discuss-fourth-quarter-mx5j4g5c7y16.html

User Image Chris_84 Posted - 3 months ago

$MOLN https://www.linkedin.com/posts/molecular-partners-ag-zurich-switzerland_radioligand-radiopharma-darpins-activity-7156638747646705664-f5-d?utm_source=share&utm_medium=member_ios

User Image Taft111211 Posted - 3 months ago

$MOLN what happened last year to cause the massive loss from jan -march?

User Image risenhoover Posted - 3 months ago

$MOLN / Molecular Partners AG - Depositary Receipt () files form 6-K https://fintel.io/doc/sec-molecular-partners-ag-1745114-6k-2024-january-08-19730-1174?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image OpenOutcrier Posted - 3 months ago

$MOLN (+7.5% pre) Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - SI https://ooc.bz/l/21540

User Image OpenOutcrier Posted - 3 months ago

$MOLN (+7.8% pre) Molecular Partners, Orano to collaborate on RDT therapies for cancer - SA https://ooc.bz/l/21506

User Image Kimbeomchul Posted - 3 months ago

$MOLN https://stkt.co/P9wA_xHM this means they have positive results to show other

User Image Stock_Titan Posted - 3 months ago

$MOLN Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference https://www.stocktitan.net/news/MOLN/molecular-partners-provides-updates-at-42nd-annual-j-p-morgan-6xl9y9y15gbj.html

User Image DonCorleone77 Posted - 3 months ago

$MOLN 2 of 2 - Molecular Partners, Orano Med enter pact to develop Radio-DARPin therapeutics ....This agreement represents the first co-development deal for Molecular Partners and Orano Med. Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.

User Image DonCorleone77 Posted - 3 months ago

$MOLN 1 of 2 - Molecular Partners, Orano Med enter pact to develop Radio-DARPin therapeutics Molecular Partners and Orano Med have announced a collaboration to develop novel Radio-DARPin therapeutics, or RDTs, that use Orano Med's 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their unique capabilities to enable rapid clinical development and agree to share costs for preclinical and clinical development for multiple oncology targets, the first of which is DLL3. The partnership is based upon strong preclinical data supporting a highly differentiated profile for 212Pb-based RDTs. Besides strong binding to target proteins and selective delivery of radioactive payloads, these data have also indicated the ability of RDTs to minimize kidney damage often associated with protein-based radioligand therapies while maintaining high tumor uptake....

User Image risenhoover Posted - 3 months ago

$MOLN / Molecular Partners AG - Depositary Receipt () files form 6-K https://fintel.io/doc/sec-molecular-partners-ag-1745114-6k-2024-january-05-19727-8478?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Stock_Titan Posted - 3 months ago

$MOLN Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies https://www.stocktitan.net/news/MOLN/molecular-partners-and-orano-med-announce-co-development-agreement-b512pyybuqww.html

User Image tradingtwenty Posted - 3 months ago

Top 5 stocks by highest volume percent change (today vs 3-month average): $OMGA 35384.95% 🔥 $MOLN 16731.19% $JFBR 9745.23% $ATXI 8157.16% $OPK 4289.84% Link: https://tradingtwenty.com/dashboard/trending/past

User Image dividendinvestorbyeagle Posted - 3 months ago

$MOLN close increased > 10% (ADR/Molecular Partners AG) https://www.dividendinvestor.com/dividend-news/?symbol=moln http://dlvr.it/T0zCyN

User Image StockMET Posted - 3 months ago

$MOLN low floater gem 💎

User Image Dieseld28 Posted - 3 months ago

$MOLN

User Image tradingtwenty Posted - 3 months ago

Top 5 after-hours stocks that have trended in the past 24 hours: $MOLN 10.40% 🔥 $CRVO 8.38% $BOWL 6.58% $RGP 6.50% $LAES 4.94% Link: https://tradingtwenty.com/dashboard/trending/past

User Image prohibited Posted - 3 months ago

$MOLN low volume but lovely price action ,reminds me of ultra runner: $ZJYL

User Image Dieseld28 Posted - 3 months ago

$MOLN 🧐

User Image Coolhandd Posted - 3 months ago

$MOLN is getting found. Could get funky $LAES $NEXI $ABVC

Analyst Ratings
JP Morgan Neutral Dec 5, 23
SVB Leerink Market Perform Aug 29, 22
Credit Suisse Neutral May 25, 22
SVB Leerink Outperform Apr 27, 22
SVB Leerink Outperform Jan 14, 22
SVB Leerink Outperform Aug 27, 21
Cowen & Co. Outperform Jul 13, 21